- Home
- REFI vs XOMA Comparison
REFI vs XOMA Comparison
Compare REFI & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REFI
- XOMA
- Stock Information
- Founded
- REFI 2021
- XOMA 1981
- Country
- REFI United States
- XOMA United States
- Employees
- REFI N/A
- XOMA N/A
- Industry
- REFI Real Estate Investment Trusts
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- REFI Real Estate
- XOMA Health Care
- Exchange
- REFI Nasdaq
- XOMA Nasdaq
- Market Cap
- REFI 306.1M
- XOMA 320.8M
- IPO Year
- REFI 2021
- XOMA N/A
- Fundamental
- Price
- REFI $15.39
- XOMA $28.59
- Analyst Decision
- REFI Buy
- XOMA Strong Buy
- Analyst Count
- REFI 2
- XOMA 2
- Target Price
- REFI $20.00
- XOMA $78.50
- AVG Volume (30 Days)
- REFI 73.0K
- XOMA 18.9K
- Earning Date
- REFI 11-07-2024
- XOMA 11-05-2024
- Dividend Yield
- REFI 12.22%
- XOMA N/A
- EPS Growth
- REFI N/A
- XOMA N/A
- EPS
- REFI 1.97
- XOMA N/A
- Revenue
- REFI $55,186,946.00
- XOMA $15,239,000.00
- Revenue This Year
- REFI N/A
- XOMA $456.45
- Revenue Next Year
- REFI $4.51
- XOMA $29.84
- P/E Ratio
- REFI $7.81
- XOMA N/A
- Revenue Growth
- REFI 5.63
- XOMA 277.95
- 52 Week Low
- REFI $13.86
- XOMA $14.27
- 52 Week High
- REFI $17.65
- XOMA $30.50
- Technical
- Relative Strength Index (RSI)
- REFI 42.89
- XOMA 53.55
- Support Level
- REFI $15.37
- XOMA $28.66
- Resistance Level
- REFI $15.85
- XOMA $30.50
- Average True Range (ATR)
- REFI 0.13
- XOMA 1.07
- MACD
- REFI -0.00
- XOMA 0.21
- Stochastic Oscillator
- REFI 22.22
- XOMA 55.56
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.